Pharmacogenomic approaches for tailored anti-leukemic therapy in children

G. Stocco, R. Franca, F. Verzegnassi, M. Londero, M. Rabusin, G. Decorti

Research output: Contribution to journalArticlepeer-review


Several lympholytic and cytotoxic agents are used in acute lymphoblastic leukemia (ALL) polychemotherapy. Genetic variants for cellular components involved in the pharmacokinetics and pharmacodynamics of these drugs can influence the pharmacological response, and molecular characterization of these genetic variants could be helpful for the comprehension of the mechanisms of resistance or increased sensitivity. The purpose of this review is to carry out an update of recent publications on genes that might influence ALL treatment in terms of outcome and/or toxicity and to underlie the role of genetic variants, particularly single nucleotide polymorphisms (SNP), in predicting clinical response, with particular reference to the current protocol for ALL therapy used in Italy, AIEOP-BFM ALL 2009.

Original languageEnglish
Pages (from-to)2237-2253
Number of pages17
JournalCurrent Medicinal Chemistry
Issue number17
Publication statusPublished - Jun 2013


  • Acute lymphoblastic leukemia
  • Chemotherapy
  • Pharmacogenetics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Pharmacogenomic approaches for tailored anti-leukemic therapy in children'. Together they form a unique fingerprint.

Cite this